Last updated: Monday September 14, 2020 KSA 19:23 – GMT 16:23
Publication date: Monday September 14, 2020 KSA 19:01 – GMT 16:01
Source: Dubai – Arabia.net
–
The CEO of the American pharmaceutical company Pfizer, Albert Burla, said that the Corona virus vaccine that the company is developing can be distributed to Americans before the end of the year if it is found to be safe and effective.
Burla said during an interview on the American CNBC network, seen by Al Arabiya.net, that the drug company should have basic data from its recent experience to the Food and Drug Administration by the end of October, adding that if the Food and Drug Administration approves the vaccine, the company is ready to distribute “Hundreds of thousands of doses.”
Because of the pandemic, health officials and drug makers in the United States have worked to accelerate the development of potential vaccines by investing in multiple stages of research although doing so may be wasted if the vaccine ends up being ineffective or safe.
The giant American pharmaceutical company is working alongside the German pharmaceutical company BioNTech.
And in July, the US government announced that it would pay companies $ 1.95 billion to produce and deliver 100 million doses of its vaccine if it proved safe and effective. The deal was signed as part of the Trump administration’s efforts to accelerate the development and production of vaccines and treatments to combat the Coronavirus.
Burla said the company has already invested $ 1.5 billion to develop the potential vaccine. He said if the vaccine failed it would be financially “painful” for the company.
“At the end of the day, that’s just the money. But that won’t break the company, although it will hurt.”
The experimental Pfizer vaccine contains a genetic material called messenger RNA, or mRNA, which scientists hope will stimulate the immune system to fight the virus.
Pfizer is one of three companies in the final stage of vaccine testing. The other two are Moderna and AstraZenka, who announced Saturday that they will resume the experiment after a temporary suspension for safety reasons.
On Saturday, Pfizer submitted a proposal to the FDA to expand the final phase of the trial, to include up to 44,000 participants, a significant increase from its previous target of 30,000.
– .
